1. Home
  2. MYGN

as of 12-05-2025 4:00pm EST

$7.09
$0.24
-3.27%
Stocks Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances Nasdaq

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.

Chart Type:
Time Range:
Founded: 1991 Country:
United States
United States
Employees: N/A City: SALT LAKE CITY
Market Cap: 625.5M IPO Year: 1995
Target Price: $12.58 AVG Volume (30 days): 1.1M
Analyst Decision: Hold Number of Analysts: 13
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -4.36 EPS Growth: N/A
52 Week Low/High: $3.76 - $16.63 Next Earning Date: 11-03-2025
Revenue: $825,300,000 Revenue Growth: 0.21%
Revenue Growth (this year): 0.1% Revenue Growth (next year): 5.28%

AI-Powered MYGN Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 3 days ago

AI Recommendation

hold
Model Accuracy: 70.47%
70.47%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Myriad Genetics Inc. News

MYGN Breaking Stock News: Dive into MYGN Ticker-Specific Updates for Smart Investing

All MYGN News

Share on Social Networks: